Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

robot
Abstract generation in progress

Agilent Technologies announced its participation in the USCAP 2026 Annual Meeting to showcase advancements in precision oncology and digital pathology. The company will highlight expanded biomarker testing capabilities, including a new PD-L1 indication, and demonstrate end-to-end digital pathology workflows designed to improve laboratory efficiency. Agilent will also collaborate with digital pathology ecosystem partners to present interoperable solutions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments